ENB-105 is under development for the treatment of inflammatory bowel disease and immune checkpoint inhibitor colitis (ICI-Colitis). It is being developed based on eSTEM systems biology platform.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback